Indeed, obese patients with NAFLD exhibit decreased very‐low‐density‐lipoproteins (VLDL)‐ApoB100 secretion rates (Charlton et al. The gene discussed is APOB; the disease is metabolic dysfunction-associated steatotic liver disease.